Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform wit... Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch's products authorized for commercial marketing are AC5 Advanced Wound System and AC5 Topical Hemostat. Arch's development stage product candidates include AC5-GTM and AC5 Surgical Hemostat, among others. Show more
Insider Financial, a leading research site for microcap companies, publishes new research on Arch Therapeutics Inc (OTCBB:ARTH), Medifirst Solutions Inc (OTCMKTS:MFST), and Cellceutix Corp...
Miami, FL--(InvestorsHub NewsWire –July 14, 2016) - EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the...
Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at European Summit for Clinical Nanomedicine and Targeted Medicine in Basel, Switzerland on June 23 WELLESLEY, MA--(Marketwired...
Arch Therapeutics Inc. to Present at the LD MICRO Invitational 2014 on June 4th WELLESLEY, MA--(Marketwired - May 28, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company...
Arch Therapeutics Inc. to Present at the Third Annual Marcum MicroCap Conference WELLESLEY, MA--(Marketwired - May 27, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company...
Arch Therapeutics Appoints Chirag Shah, PhD as Vice President of R&D Engineering and Quality Systems and Peter LaCrosse as Chief of Staff Decades of Experience Adds Strength to Arch's...
Arch Therapeutics Co-Founder Rutledge Ellis-Behnke, PhD Presents at Two Scientific Meetings in March Discusses AC5(TM) at the Brainstorming Neuromodulation Workshop and 4th Annual Meeting of...
IPOs and Transactions: March 17 - 21 Last week's review of corporations, SEC form type and law firms PR Newswire NEW YORK, March 24, 2014 NEW YORK, March 24, 2014 /PRNewswire/ --Β There were 56...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.4839 | -65.3918918919 | 0.74 | 0.74 | 0.2551 | 1342 | 0.62926291 | CS |
4 | -0.4239 | -62.3382352941 | 0.68 | 0.8 | 0.1701 | 2246 | 0.58251878 | CS |
12 | -0.5739 | -69.1445783133 | 0.83 | 1.05 | 0.1701 | 2505 | 0.70709367 | CS |
26 | -1.8639 | -87.9198113208 | 2.12 | 2.14 | 0.1701 | 2732 | 1.03641761 | CS |
52 | -1.2939 | -83.4774193548 | 1.55 | 18 | 0.1701 | 10182 | 4.88775987 | CS |
156 | -23.7439 | -98.9329166667 | 24 | 28 | 0.1701 | 135070 | 11.67208905 | CS |
260 | -47.7439 | -99.4664583333 | 48 | 59 | 0.1701 | 243310 | 24.61237669 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.